特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
312457

勃起機能不全(ED)治療薬の世界市場:2019年~2023年

Global Erectile Dysfunction (ED) Drugs Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 121 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.70円
勃起機能不全(ED)治療薬の世界市場:2019年~2023年
出版日: 2019年03月27日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 121 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

EDにつながる症状の高い有病率は、今後数年間で市場成長をもたらすと予想される重要な要素の1つとなっています。糖尿病、高血圧、肥満、鬱病、ストレス、および過剰なアルコール摂取を含む様々な健康状態によって、高齢者および若者の間でEDの発生率が上昇しています。これらの症状はホルモン、酵素、および他の要因の正常な生理的レベルを直接変えるので、近年、陰茎勃起を含む問題はかなり急増しています。これらの問題により、勃起機能不全治療薬市場は今後数年間で大幅な成長を記録する見込みです。 Technavioのアナリストは、世界の勃起機能不全(ED)治療薬市場が2023年までに4%以上のCAGRで成長すると予測しています。

当レポートでは、世界の勃起機能不全(ED)治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第7章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 経口薬
  • 外用薬
  • その他
  • 市場機会:製品別

第8章 顧客情勢

第9章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

第15章 付録

  • 調査方法
  • 略語のリスト

第16章 TECHNAVIOについて

図表
  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for ED
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Oral drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Sales of VIAGRA and CIALIS 2016-2018
  • Exhibit 23: Topical drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Topical drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Bayer AG - Vendor overview
  • Exhibit 48: Bayer AG - Business segments
  • Exhibit 49: Bayer AG - Organizational developments
  • Exhibit 50: Bayer AG - Geographic focus
  • Exhibit 51: Bayer AG - Segment focus
  • Exhibit 52: Bayer AG - Key offerings
  • Exhibit 53: Eli Lilly and Company - Vendor overview
  • Exhibit 54: Eli Lilly and Company - Business segments
  • Exhibit 55: Eli Lilly and Company - Organizational developments
  • Exhibit 56: Eli Lilly and Company - Geographic focus
  • Exhibit 57: Eli Lilly and Company - Segment focus
  • Exhibit 58: Eli Lilly and Company - Key offerings
  • Exhibit 59: Pfizer Inc. - Vendor overview
  • Exhibit 60: Pfizer Inc. - Business segments
  • Exhibit 61: Pfizer Inc. - Organizational developments
  • Exhibit 62: Pfizer Inc. - Geographic focus
  • Exhibit 63: Pfizer Inc. - Segment focus
  • Exhibit 64: Pfizer Inc. - Key offerings
  • Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 68: Teva Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 69: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 70: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 71: VIVUS Inc. - Vendor overview
  • Exhibit 72: VIVUS Inc. - Business segments
  • Exhibit 73: VIVUS Inc. - Organizational developments
  • Exhibit 74: VIVUS Inc. - Geographic focus
  • Exhibit 75: VIVUS Inc. - Key offerings
  • Exhibit 76: Validation techniques employed for market sizing
目次
Product Code: IRTNTR31071

About this market

The high prevalence of conditions resulting in ED is one of the key factors expected to trigger the market's growth in the forthcoming years. Various health conditions including diabetes, hypertension, obesity, depression, stress, and excessive alcohol consumption are resulting in the rising incidences of ED among elderly as well as young people. As these conditions directly alter the normal physiological levels of hormones, enzymes, and other factors, problems including penile erection have surged considerably in the recent years. These issues will further lead the erectile dysfunction drugs market to register a significant growth in the forthcoming years. Technavio's analysts have predicted that the erectile dysfunction (ED) drugs market will register a CAGR of over 4% by 2023.

Market Overview

Rising demand for ED drugs

One of the growth drivers of the global erectile dysfunction (ED) drugs market is the rising demand for ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are expected to propel the growth of the global erectile dysfunction (ED) drugs market during the forecast period.

Side effects of available drugs

One of the challenges in the growth of the global erectile dysfunction (ED) drugs market is the side effects of available drugs. The alterations in the blood flow, which are caused by ED drugs, result in side-effects such as headache, vision changes, and dizziness, which will hinder the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the erectile dysfunction (ED) drugs market during 019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Many vendors in the market are focusing on expanding research for the development of novel therapies such as stem cells for the treatment of ED. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Oral drugs - Market size and forecast 2018-2023
  • Topical drugs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.